Results 111 to 120 of about 10,714 (176)

RETRACTED: NFIC suppressed the development of Glioma via modulating the balance of SHP2/PI3K and NF-κB/PTEN Signaling.

PLoS One
Bao H, Liu K, Gao N, Su Y, Bai H, Dou C, Jiang F, Wang F.   +7 more
europepmc   +1 more source

CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer. [PDF]

J Exp Clin Cancer Res
Mulero-Sánchez A, Bosma A, Visuvasam B, Pouliopoulou N, van de Ven M, Proost N, Boeije M, Lieftink C, Beijersbergen R, Bernards R, Mainardi S.   +10 more
europepmc   +1 more source

TEAD inhibitors synergize with MEK, SHP2 and mTOR inhibitors in NF1 and NF2 cell lines. [PDF]

MicroPubl Biol
Yang Y, Gurunathan S, Schechter S, Field J.   +3 more
europepmc   +1 more source

Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. [PDF]

Signal Transduct Target Ther
Hafner P, Keller SJ, Chen X, Alrawashdeh A, Jumaa H, Nollmann FI, Besson S, Kemming J, Gorka O, Das T, Appiah B, Lehmann A, Li M, Apostolova P, Bengsch B, Zeiser R, Tholen S, Schilling O, Groß O, Vlachos A, Wittel UA, von Elverfeldt D, Reichardt W, Boerries M, Andrieux G, Heynen GJ, Fichtner-Feigl S, Hannibal L, Ruess DA.   +28 more
europepmc   +1 more source

Phosphatase SHP2 pathogenic mutations enhance activity by altering conformational sampling. [PDF]

Proc Natl Acad Sci U S A
Glaser AW, Pádua RAP, Ojoawo AM, Sullivan C, Kern D.   +4 more
europepmc   +1 more source

EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-γ. [PDF]

J Clin Invest
Zhuang WT, Pang LL, Hu LY, Liao J, Zhan JH, Li T, Chen RX, Zheng JN, Li AL, Yu WY, Mao TQ, Chen L, Huang YJ, Hong SD, Li J, Wu JH, Zeng YM, Yang MJ, Zeng HQ, Zhang YX, Zhang L, Fang WF.   +21 more
europepmc   +1 more source

CBX2 promoted oral squamous cell carcinoma via increasing CEP55/NF-κB/METTL3/SHP2 signaling induced metastasis/proliferation and angiogenesis. [PDF]

Sci Rep
Ma S, Wang Z, Li C, Liu Z, Zhang X.
europepmc   +1 more source

CD300a as a Potential Immune Checkpoint in Breast Cancer: Insights from in vivo and in vitro Models.

Int Arch Allergy Immunol
Ben-Zimra M, Niazov S, Rahimli Alekberli F, Levi-Schaffer F.   +3 more
europepmc   +1 more source

Decoding C‑SH2 Domain/Peptide Interactions in SH2 Domain-Containing Tyrosine Phosphatase 2: A Molecular Framework for Rational Inhibitor Design. [PDF]

ACS Omega
Innamorati C, Bruno L, Calligari P, Bocchinfuso G, Stella L.   +4 more
europepmc   +1 more source

The LNK adaptor protein: a dual regulator of proliferation and migration in solid tumors. [PDF]

Mol Cell Oncol
Mantilla-Ollarves JC, Velazquez L, Rocha-Zavaleta L.   +2 more
europepmc   +1 more source